title: Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma.
abstract: Sorafenib is the standard treatment of hepatocellular carcinoma (HCC). However, fibrolamellar HCC was not included in sorafenib trials. The case is a 26-year-old man with fibrolamellar HCC, who had a cerebrovascular accident (CVA) while being treated with sorafenib. This illustrates a probable relationship between use of sorafenib and CVA in low cardiovascular risk patients.
authors.affiliation: Department of Hepatology and Gastroenterology, Ghent University B-9000, Ghent, Belgium.
authors.forename: Yves-Paul
authors.initials: YP
authors.lastname: Vandewynckel
authors.affiliation: Department of Hepatology and Gastroenterology, Ghent University B-9000, Ghent, Belgium.
authors.forename: Anja
authors.initials: A
authors.lastname: Geerts
authors.affiliation: Department of Hepatology and Gastroenterology, Ghent University B-9000, Ghent, Belgium.
authors.forename: Xavier
authors.initials: X
authors.lastname: Verhelst
authors.affiliation: Department of Hepatology and Gastroenterology, Ghent University B-9000, Ghent, Belgium.
authors.forename: Hans
authors.initials: H
authors.lastname: Van Vlierberghe
keywords: Carcinoma; drug toxicity; fibrolamellar hepatocellular carcinoma; hepatocellular; sorafenib; stroke